Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$20.31
-2.1%		$16.55
$7.48
▼
$20.94
$2.26B-0.21.62 million shs1.83 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.17
-3.8%		$7.70
$1.95
▼
$12.43
$7.51B0.019.06 million shs9.32 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$38.62
-2.2%		$36.65
$14.32
▼
$41.23
$7.97B0.76955,058 shs669,668 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$54.08
-3.4%		$53.25
$29.08
▼
$65.00
$7.81B1.22991,865 shs793,221 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%+10.32%+11.17%+26.86%+154.83%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.00%+0.99%-24.05%+0.84%+180.08%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%-2.00%-0.44%+42.40%+132.37%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-1.06%-7.38%-5.01%+55.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$20.31
-2.1%		$16.55
$7.48
▼
$20.94
$2.26B-0.21.62 million shs1.83 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.17
-3.8%		$7.70
$1.95
▼
$12.43
$7.51B0.019.06 million shs9.32 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$38.62
-2.2%		$36.65
$14.32
▼
$41.23
$7.97B0.76955,058 shs669,668 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$54.08
-3.4%		$53.25
$29.08
▼
$65.00
$7.81B1.22991,865 shs793,221 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%+10.32%+11.17%+26.86%+154.83%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.00%+0.99%-24.05%+0.84%+180.08%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%-2.00%-0.44%+42.40%+132.37%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-1.06%-7.38%-5.01%+55.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
2.90
Moderate Buy$24.6321.25% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$14.2098.05% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.50
Moderate Buy$42.119.04% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.44
Hold$86.0059.02% Upside

Current Analyst Ratings Breakdown

Latest AMLX, IMVT, PCVX, and IBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/20/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$21.00 ➝ $24.00
7/14/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/10/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/6/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/6/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/30/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$57.00 ➝ $61.00
6/25/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$30.00 ➝ $40.00
6/8/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$34.00
6/2/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$15.00
5/26/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $62.00
5/22/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$23.00 ➝ $30.00
(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M25.85N/AN/A$2.78 per share7.31
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M66.29N/AN/A($0.51) per share-14.06
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$20.51 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/6/2026 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)

Latest AMLX, IMVT, PCVX, and IBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609N/AN/AN/AN/AN/A
8/6/2026Q1 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.6181N/AN/AN/AN/AN/A
8/5/2026Q2 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$2.06N/AN/AN/A$12.50 millionN/A
8/4/2026Q2 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08N/AN/AN/A$49.70 millionN/A
5/20/2026Q4 2026
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.60-$0.73-$0.13-$0.73N/AN/A
5/7/2026Q1 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.34-$0.37-$0.03-$0.37N/AN/A
5/7/2026Q1 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million
5/6/2026Q1 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
17.85
17.85
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
6.67
6.66
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
9.09
9.09
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
7.49
7.49

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
200111.19 million99.07 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5901.05 billion355.05 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120206.40 million202.48 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160144.40 million139.63 millionOptionable

Recent News About These Companies

Seven Fleet Capital Management LP Buys 103,085 Shares of Vaxcyte, Inc. $PCVX
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-buys-103085-shares-of-vaxcyte-inc-pcvx-2026-08-02/
DV Trading LLC Takes Position in Vaxcyte, Inc. $PCVX
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dv-trading-llc-takes-position-in-vaxcyte-inc-pcvx-2026-08-02/
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB) and Vaxcyte (PCVX)
July 31 at 8:32 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BIIB-Q/pressreleases/3572153/analysts-offer-insights-on-healthcare-companies-ge-healthcare-technologies-inc-gehc-biogen-biib-and-vaxcyte-pcvx/
Vaxcyte Inc : pcvx
July 30 at 11:30 PM  |  247wallst.comhttps://247wallst.com/companies/pcvx/
59,061 Shares in Vaxcyte, Inc. $PCVX Purchased by Stempoint Capital LP
July 30 at 6:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-59061-shares-in-vaxcyte-inc-pcvx-purchased-by-stempoint-capital-lp-2026-07-30/
Janus Henderson Group PLC Acquires 3,188,687 Shares of Vaxcyte, Inc. $PCVX
July 30 at 5:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-janus-henderson-group-plc-acquires-3188687-shares-of-vaxcyte-inc-pcvx-2026-07-30/
Vaxcyte (NASDAQ:PCVX) Stock, Earnings Estimates, EPS, And Revenue
July 29, 2026  |  benzinga.comhttps://www.benzinga.com/quote/PCVX/earnings
Vaxcyte (PCVX) Projected to Release Quarterly Earnings on Wednesday
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxcyte-pcvx-projected-to-release-quarterly-earnings-on-wednesday-2026-07-29/
Readystate Asset Management LP Sells 95,547 Shares of Vaxcyte, Inc. $PCVX
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-readystate-asset-management-lp-sells-95547-shares-of-vaxcyte-inc-pcvx-2026-07-29/
ADAR1 Capital Management LLC Trims Holdings in Vaxcyte, Inc. $PCVX
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-trims-holdings-in-vaxcyte-inc-pcvx-2026-07-29/
Vaxcyte (NASDAQ:PCVX) CEO Grant Pickering Sells 16,198 Shares of Stock
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxcyte-nasdaqpcvx-ceo-grant-pickering-sells-16198-shares-of-stock-2026-07-28/
Eversept Partners LP Has $53.70 Million Stock Position in Vaxcyte, Inc. $PCVX
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eversept-partners-lp-has-5370-million-stock-position-in-vaxcyte-inc-pcvx-2026-07-28/
Maverick Capital Ltd. Has $80.06 Million Stock Position in Vaxcyte, Inc. $PCVX
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-maverick-capital-ltd-has-8006-million-stock-position-in-vaxcyte-inc-pcvx-2026-07-28/
Vaxcyte, Inc. $PCVX Shares Purchased by SummitTX Capital L.P.
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vaxcyte-inc-pcvx-shares-purchased-by-summittx-capital-lp-2026-07-28/
Vaxcyte, Inc. $PCVX Stake Boosted by Elmind Capital LP
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vaxcyte-inc-pcvx-stake-boosted-by-elmind-capital-lp-2026-07-28/
Bank of New York Mellon Corp Has $27.57 Million Stock Holdings in Vaxcyte, Inc. $PCVX
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-has-2757-million-stock-holdings-in-vaxcyte-inc-pcvx-2026-07-28/
First Light Asset Management LLC Takes Position in Vaxcyte, Inc. $PCVX
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-light-asset-management-llc-takes-position-in-vaxcyte-inc-pcvx-2026-07-27/
Vaxcyte, Inc. $PCVX Shares Sold by Spruce Street Capital LP
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vaxcyte-inc-pcvx-shares-sold-by-spruce-street-capital-lp-2026-07-25/
Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential
July 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4924165-vaxcyte-clinical-stage-vaccine-disrupter-with-vast-near-potential
112,631 Shares in Vaxcyte, Inc. $PCVX Bought by WCM Investment Management LLC
July 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-112631-shares-in-vaxcyte-inc-pcvx-bought-by-wcm-investment-management-llc-2026-07-21/
Jennison Associates LLC Increases Stake in Vaxcyte, Inc. $PCVX
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jennison-associates-llc-increases-stake-in-vaxcyte-inc-pcvx-2026-07-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$20.31 -0.44 (-2.12%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$19.75 -0.56 (-2.76%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$7.17 -0.28 (-3.76%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$7.20 +0.03 (+0.42%)
As of 07/31/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$38.62 -0.86 (-2.18%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$38.62 0.00 (-0.01%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$54.08 -1.88 (-3.36%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$54.07 -0.01 (-0.02%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas